$93.03
Value $11.0B
HALO and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$93.03
Value $11.0B
$134.62
Value $333B
Halozyme Therapeutics (HALO) has a market value of $11.0B and Merck & Company (MRK) $333B. Over the last year, with dividends, HALO moved +32.4% and MRK +45.8%. The P/E is 22.6 for HALO and 135.7 for MRK. Dividend yield: HALO none, MRK 2.53%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
HALO$11.0B
MRK$333B
MRK is 30 times HALO
Revenue, 12 months
HALO$1.8B
MRK$67.4B
MRK is 37 times HALO
Net income, 12 months
HALO$485M
MRK$2.5B
MRK is 5.1 times HALO
Operating margin
HALO37.4%
MRK–
ROIC
HALO20.7%
MRK3.9%
16.8 points apart
P/E
HALO22.6
MRK135.7
MRK is 6.0 times HALO
Dividend yield
HALO0.0%
MRK2.5%
2.5 points apart
5-year return
HALO+161.9%
MRK+94.3%
67.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
HALO+161.9%
MRK+94.3%
| Period | HALOWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +32.4%Price +32.4% | +45.8%Price +41.6% |
| 3 years since November 20, 2023 | +132.5%+32.5% a yearPrice +132.5% | +43.7%+12.8% a yearPrice +31.1% |
| 5 years since November 19, 2021 | +161.9%+21.2% a yearPrice +161.9% | +94.3%+14.2% a yearPrice +66.8% |
| 10 years since November 21, 2016 | +636.1%+22.1% a yearPrice +636.1% | +207.2%+11.9% a yearPrice +126.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
HALOHalozyme TherapeuticsMRKMerck & Company
| Price | $93.03 | $134.62 |
|---|---|---|
| Market value | $11.0B | $333B |
| Enterprise value (EV) | $13.2B | $377B |
| P/E | 22.6 | 135.7 |
| P/E, 5-year median | 17.6 | 14.8 |
| P/B | – | 7.4 |
| EV/EBIT | 19.5 | 79.2 |
| Free cash flow yield | 8.1% | 4.4% |
| Revenue, 12 months | $1.8B | $67.4B |
|---|---|---|
| Net income, 12 months | $485M | $2.5B |
| Free cash flow, 12 months | $886M | $14.7B |
| Earnings per share, 12 months | $4.01 | $0.98 |
| Revenue growth, year on year | 37.6% | 1.3% |
| Revenue growth a year, past | +39.2%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | +23.0%over 5 years | +21.2%over 5 years |
| Gross margin | 82.3% | 71.8% |
|---|---|---|
| Operating margin | 37.4% | – |
| Net margin | 26.9% | 3.6% |
| ROIC | 20.7% | 3.9% |
| ROE | 282.0% | 5.2% |
| Cash | $1.1B | $9.7B |
|---|---|---|
| Total debt | $3.3B | $53.8B |
| Net debt / EBITDA | 3.2 | 5.7 |
| Interest cover | 30.6× | 2.4× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | 3.1% | 1.5% |
| Shareholder yield | 3.1% | 4.1% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($333B) is about 30.3 times Halozyme Therapeutics ($11.0B), at today's prices.
Since November 21, 2016, HALO's price moved +636.1% and MRK's +126.4%. With dividends: HALO +636.1% (+22.1% a year), MRK +207.2% (+11.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Halozyme Therapeutics and 2.53% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 22.6 for HALO and 135.7 for MRK. The median of the last five years was 17.6 and 14.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 26.9% for Halozyme Therapeutics and 3.6% for Merck & Company, and the operating margin 37.4% and –. Revenue was $1.8B and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.